P-185 A prospective, randomized, controlled, multicenter phase III clinical trial of apatinib combined with neoadjuvant chemoradiotherapy for patients with locally advanced, HER2-negative, Siewert’s type II-III adenocarcinoma of esophagogastric junction

In recent years, the incidence of adenocarcinomas of the esophagogastric junction (AEG), with a poor prognosis, is increasing. Surgical resection is the primary curative paradigm in the treatment of AEG patients, while the prognosis remains woeful. A number of randomized clinical trials has shown that neoadjuvant chemoradiotherapy or neoadjuvant chemotherapy is more beneficial than surgery alone. From May 2018 to May 2019, 31 AEG patients with...